Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease

References

• Tuazon S, Holmberg L, Nadeem O, et al. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021;11(2):1. doi: 10.1038/s41408-021-00414-6.
   PubMed Web of Science ®Google Scholar
• Bhutani M, Foureau D, Atrash S, et al. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1–11. doi: 10.1038/s41375-019-0660-0.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e48. doi: 10.1016/S1470-2045(14)70442-5.
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernández DE Larrea C, Rosiñol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–3812. doi: 10.1200/JCO.2011.34.9290.
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Vanderkerken K, VAN Camp B, et al. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008;25(4):325–334. doi: 10.1007/s10585-007-9108-4.
   PubMed Web of Science ®Google Scholar
• Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11(9):161. doi: 10.1038/s41408-021-00527-y.
   PubMed Web of Science ®Google Scholar
• Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843–850. doi: 10.1111/bjh.13382.
   PubMed Web of Science ®Google Scholar
• Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–364. doi: 10.3324/haematol.2013.094409.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330. doi: 10.1093/annonc/mdp329.
   PubMed Web of Science ®Google Scholar
• Beksac M, Seval GC, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan myeloma study group and barcelona university: analysis of parameters that improve outcome. Haematologica. 2021;106(4):1228–1228. doi: 10.3324/haematol.2020.278272.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema D-J, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica. 2018;103(5):890.
   PubMed Web of Science ®Google Scholar
• Deng S, Xu Y, An G, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15(5):286–291. doi: 10.1016/j.clml.2014.12.013.
   PubMed Web of Science ®Google Scholar
• Usmani S, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–1767. doi: 10.3324/haematol.2012.065698.
   PubMed Web of Science ®Google Scholar
• Jagosky MH, Usmani SZ. Extramedullary disease in multiple myeloma. Curr Hematol Malig Rep. 2020;15(2):62–71. doi: 10.1007/s11899-020-00568-3.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol. 2022;40(20):2246–2256. doi: 10.1200/JCO.21.01676.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gatt M, Rouvio O, et al. Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol. 2016;172(1):89–96. doi: 10.1111/bjh.13799.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim J, Jeon Y, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94(3):445–452. doi: 10.1007/s00277-014-2216-8.
   PubMed Web of Science ®Google Scholar
• Short K, Rajkumar S, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–908. doi: 10.1038/leu.2011.29.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Sevcikova T, Zihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36(1):288–291. doi: 10.1038/s41375-021-01343-w.
   PubMed Web of Science ®Google Scholar
• Han W, Jin Y, Xu M, et al. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. Hematology. 2021;26(1):510–517. doi: 10.1080/16078454.2021.1948208.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. doi: 10.1016/S1470-2045(16)30206-6.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Aljawai Y, Morgan E, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–858. doi: 10.1111/bjh.13383.
   PubMed Web of Science ®Google Scholar
• Minnema M, VAN DE Donk N, Zweegman S, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008;41(9):779–784. doi: 10.1038/sj.bmt.1705982.
   PubMed Web of Science ®Google Scholar
• He J, Yue X, He D, et al. Multiple Extramedullary-Bone related and/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma. Front Oncol. 2021;11:668099. doi: 10.3389/fonc.2021.668099.
   PubMed Web of Science ®Google Scholar
• Chng W, Dispenzieri A, Chim C, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–277. doi: 10.1038/leu.2013.247.
   PubMed Web of Science ®Google Scholar
• Billecke L, Murga Penas E, May A, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161(1):87–94. doi: 10.1111/bjh.12223.
   PubMed Web of Science ®Google Scholar
• Rasche L, Bernard C, Topp M, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol. 2012;91(7):1031–1037. doi: 10.1007/s00277-012-1414-5.
   PubMed Web of Science ®Google Scholar
• Sheth N, Yeung J, Chang H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33(10):1357–1360. doi: 10.1016/j.leukres.2009.01.010.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, et al. Multiple myeloma involving Central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–284. doi: 10.1111/j.1365-2141.2004.05199.x.
   PubMed Web of Science ®Google Scholar
• Li L T, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep. 2015;11(3):1566–1572. doi: 10.3892/mmr.2014.2914.
   PubMed Web of Science ®Google Scholar
• Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126(13):1536–1543. doi: 10.1182/blood-2015-06-653261.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971–976. doi: 10.1182/blood-2015-07-635383.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–1596. doi: 10.1182/blood-2012-02-408922.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Fonseca R, Siegel D, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174–1180. doi: 10.1182/blood-2016-03-707596.
   PubMed Web of Science ®Google Scholar
• Kumar L, Gogi R, Patel A, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplant. 2017;52(10):1473–1475. doi: 10.1038/bmt.2017.165.
   PubMed Web of Science ®Google Scholar
• Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96(1):73–80. doi: 10.1007/s00277-016-2847-z.
   PubMed Web of Science ®Google Scholar
• Yee AJ, Huff CA, Chari A, et al. Response to therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with penta-exposed triple-class refractory myeloma who had plasmacytomas. Blood. 2019;134(Supplement_1):3140–3140. doi: 10.1182/blood-2019-129038.
   Google Scholar
• Xu J, Chen L-J, Yang S-S, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543–9551. doi: 10.1073/pnas.1819745116.
   PubMed Web of Science ®Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688–1700. doi: 10.1182/blood-2016-04-711903.
   PubMed Web of Science ®Google Scholar
• Zhou X, Flüchter P, Nickel K, et al. Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease. Cancers (Basel). 2020;12(4):1035. doi: 10.3390/cancers12041035.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu J, Zhao W-H, et al. Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease–a single institution observation in China. Blood. 2020;136(Supplement 1):6–6. doi: 10.1182/blood-2020-140243.
   PubMedGoogle Scholar
• Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [F]fluorodeoxyglucose positron emission Tomography-Computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–2918. doi: 10.1200/JCO.2017.72.2975.
   PubMed Web of Science ®Google Scholar
• D’agostino M, Cairns D, Lahuerta J, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–3418. doi: 10.1200/JCO.21.02614.
   PubMed Web of Science ®Google Scholar
• Abdallah N, Binder M, Rajkumar S, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. doi: 10.1038/s41408-022-00611-x.
   PubMed Web of Science ®Google Scholar